Discover our Portfolio
Abivax, listed on Euronext (ISIN : FR0012333284 – Mnémo : ABVX), is a biotechnology company targeting the immune system to eliminate viral and inflammatory diseases based on its unique technological platforms (“antiviral” platform, “immune stimulation” platform and “polyclonal antibodies” platform).
Its most advanced product, ABX464, a potential functional cure for HIV, is currently in Phase II clinical trials. Abivax is developing the same candidate in ulcerative colitis (currently in phase 2a).
Abivax is also developing several preclinical candidates for other viruses (Influenza, Dengue, and others).
2017 was a positive year for ABIVAX, which made significant progress in its R&D. ABX464, a novel oral molecule that inhibits viral replication via a single anti-inflammatory mode of action, has shown in 2 clinical studies that it induces a reduction of the HIV virus reservoir by up to 50% after only one month of treatment.
The outlook for 2018 is encouraging as the first results from longer-term treatment are expected mid-2018. Abivax also plans to file regulatory submissions in the US and Europe in mid-2018 to initiate a Phase IIb clinical trial for the use of ABX464 for HIV patients.